ENPP2 and hepatocellular carcinoma: Similar results have been obtained with the ATX inhibitors AM063 and AM095, which mitigated fibrosis progression and reduced development of HCC by disrupting validated HCC risk gene signatures in cirrhosis-driven HCC rat models [181].